We are international
Donate
TEXT SIZE   


NLB New Publications and Resources

Scroll down to learn more.

08.04.16
 

August 2016

In This Issue:

Webcasts from 2016 ONS Satellite Symposium:

Case Study 1:   Newly Diagnosed Multiple Myeloma, Diagnostic Criteria, Response, Extended Treatment Team, Shared Decision Making, Minimal Residual Disease

Case Studies 2 & 3: Newly Diagnosed MM, 1+ Prior Therapies, Bone Health, Renal Health, Relapsed Myeloma, Immunotherapy, Clonal Evolution


Case Studies 4, 5 & 6: Relapsed Myeloma, Treatment for Relapsed Myeloma, Drugs in Development



About NLB


Co-Chairs

Beth Faiman, PhD, MSN, APRN-BC, AOCN®
Multiple Myeloma Program
Hematology/Oncology
Cleveland Clinic Foundation
Taussig Cancer Institute
Cleveland, OH

Joseph D. Tariman, PhD, ANP-BC
School of Nursing/College of
Science and Health
De Paul University
Chicago, IL

 
Faculty

Donna Catamero, ANP-BC, OCN, CCRC
Multiple Myeloma Program Mount Sinai Medical Center
New York, NY

Tiffany Richards, RN, MS, ANP-BC
Dept. of Lymphoma/Myeloma MD Anderson Cancer Center Houston, TX

Click Below for C.E. Opportunity


 

Tune in Alert

Watch this year's International Myeloma Working Group Conference Series in Vienna.

 



 
 

myeloma.org

 

 

Dear Nurse Professional,

On April 28, 2016 nurses from across the nation convened in San Antonio, Texas for the Oncology Nursing Society (ONS) 41st Annual Congress. Since 2007 the International Myeloma Foundation (IMF) Nurse Leadership Board has been granted a Satellite Symposium at the ONS Congress to provide continuing education for oncology nurses.

More than 900 nurses attended this symposium entitled,
Updates in Multiple Myeloma: Case Studies in Collaborative Nursing and Patient Care”.   Through case studies, the faculty highlighted best practices in managing myeloma patients at different stages of disease and through different types of treatment. The faculty focused on nursing implications and provided tools to build partnerships with patients and their caregivers to promote optimal survivorship.

The IMF was founded in 1990 with a mission to improve the quality of life of myeloma patients while working toward prevention and a cure. Since then, the IMF has remained fully committed to empowering patients through education, while ensuring that their doctors and nurses receive the most current information to help diagnose and treat patients with myeloma.

It is with this commitment to bring the finest education to nurse professionals that we are sharing the following webcasts from the recent symposium.

Thank you for your ongoing service to the myeloma community.


Sincerely,

Diane Moran, RN, MA, EdM
Senior Vice President Strategic Planning
International Myeloma Foundation




Multiple Myeloma Background and Case Study 1: Newly Diagnosed Multiple Myeloma, Diagnostic Criteria, Response, Extended Treatment Team, Shared Decision Making, Minimal Residual Disease

Presented by Joseph D. Tariman, PhD, ANP-BC and Beth Faiman, PhD, MSN, APRN-BC, AOCN®

Joseph D. Tariman and Beth Faiman began the symposium by presenting background information on multiple myeloma, including discussing an overview of recently approved drugs and how diagnosis has changed in recent years to include myeloma defining events, not only end organ damage (CRAB criteria). They went on to discuss the case study of a newly diagnosed patient, highlighting different ways myeloma patients tend to present, and discussing common treatment regimens, patient management, and the nurse's roles in adherence, shared decision making, and survivorship care plans.

Link Case #1 (Total time: 25:31)

Case Studies 2 & 3: Newly Diagnosed MM, 1+ Prior Therapies, Bone Health, Renal Health, Relapsed Myeloma, Immunotherapy, Clonal Evolution

Presented by Donna Catamero ANP-BC, OCN, CCRC and Beth Faiman, PhD, MSN, APRN-BC, AOCN®

Donna Catamero presented two case studies that highlighted the newly approved drugs izazomib and elotuzumab for patients who had received prior therapy for multiple myeloma; clinical pearls including best practices for patient management were included. Beth Faiman integrated recent research into each case including discussing how the research results influence shared decision making. The concepts of clonal evolution, monitoring response, and tailoring therapy to the patient were explored, as well as the nurses' role in educating patients on the important topics of bone and renal health.

Link Case #2 & #3: (Total time: 23:51)


Case Studies 4, 5 & 6: Relapsed Myeloma, Treatment for Relapsed Myeloma, Drugs in Development

Presented by Tiffany Richards, RN, MS, ANP-BC and Beth Faiman, PhD, MSN, APRN-BC, AOCN®

Tiffany Richards continued the symposium by discussing cases highlighting daratumumab, carfilzomib and pomalidomide including clinical pearls and best practices for patient management. Once again, Beth Faiman integrated current research, including the Aspire and Endeavor trials, as well as drugs in development. Tiffany closed the presentation by reviewing the many free resources the Nurse Leadership Board and the IMF have created to help nurses and their patients and caregivers.

Link Case #4, #5, #6 (Total time: 27:39)



About the Nurse Leadership Board:

 

Founded in 2006, the IMF's Nurse Leadership Board (NLB) is comprised of nurses from leading centers caring for myeloma patients across the country.

Some of the landmark publications of the NLB include:

   

To learn more about the Nurse Leadership Board – Click here or contact Diane Moran (dmoran@myeloma.org)

 

 

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
Privacy Policy | Unsubscribe | Manage My Subscriptions
myeloma.org

 related articles